{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=20", "query": { "condition": "Adult Solid Neoplasm", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 1462, "total_pages": 147, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:24:52.890Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00087217", "title": "17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087217" }, { "nct_id": "NCT01723020", "title": "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancy", "Advanced Solid Tumors", "Cancer", "Oncology", "Oncology Patients", "Tumors", "Glioblastoma", "Multiple Myeloma" ], "interventions": [ { "name": "AMG 232", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kartos Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-12-27", "completion_date": "2017-09-25", "has_results": false, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 9, "location_summary": "Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01723020" }, { "nct_id": "NCT00356980", "title": "TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "colloidal gold-bound tumor necrosis factor", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-05", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00356980" }, { "nct_id": "NCT02520713", "title": "The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pediatric Solid Tumor" ], "interventions": [ { "name": "Genetic testing and GAIN report", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 825, "start_date": "2015-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 12, "location_summary": "San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02520713" }, { "nct_id": "NCT06803680", "title": "A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "BGB-B455", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-03-18", "completion_date": "2028-04-29", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 5, "location_summary": "Celebration, Florida • Philadelphia, Pennsylvania • Sioux Falls, South Dakota + 2 more", "locations": [ { "city": "Celebration", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06803680" }, { "nct_id": "NCT06395090", "title": "A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasm Metastasis" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Favezelimab", "type": "BIOLOGICAL" }, { "name": "Favezelimab/Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab/Vibostolimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 0, "start_date": "2025-01-15", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Iowa City, Iowa • Kansas City, Missouri + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06395090" }, { "nct_id": "NCT00022113", "title": "EMD 121974 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022113" }, { "nct_id": "NCT02189174", "title": "Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "CLR457", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-08-07", "completion_date": "2015-11-12", "has_results": false, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02189174" }, { "nct_id": "NCT01631279", "title": "A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PR610", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Proacta, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-08", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2014-06-16", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01631279" }, { "nct_id": "NCT01004224", "title": "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3", "Squamous Lung Cancer With FGFR1 Amplification", "Bladder Cancer With FGFR3 Mutation or Fusion", "Advanced Solid Tumors With FGFR1 Amplication", "Advanced Solid Tumors With FGFR2 Amplication", "Advanced Solid Tumors With FGFR3 Mutation" ], "interventions": [ { "name": "BGJ398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2009-12-11", "completion_date": "2018-10-08", "has_results": false, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-10-23T17:24:52.890Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004224" } ] }